GlassScriptPhysician profile
Meredith Lee Kirk
NPI 1891233235
$12,586.47
in general payments reported to CMS, 2019-2025
61 companies · $4,682 in 2025
The $4,682 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $224 · 2022: $147 · 2023: $3,083 · 2024: $4,451 · 2025: $4,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,826 · Long Term Medical Supply Or Device Loan: $1,778 · Education: $332 · Consulting Fee: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,825.62 |
| Long Term Medical Supply Or Device Loan | $1,778.23 |
| Education | $331.89 |
| Consulting Fee | $280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,154.38 | 2023-2025 | |
| Pfizer INC. | $1,014.80 | 2021-2025 | |
| Celgene Corporation | $960.40 | 2023-2025 | Reblozyl, Breyanzi, Onureg |
| Astrazeneca Pharmaceuticals LP | $648.18 | 2021-2025 | Lynparza, Calquence, Enhertu |
| Janssen Biotech, INC. | $563.03 | 2021-2025 | Rybrevant, Darzalex, Erleada |
| Daiichi Sankyo INC. | $536.06 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Exelixis INC. | $496.25 | 2023-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $474.05 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $473.72 | 2023-2025 | Opdivo, Reblozyl |
| Merck Sharp & Dohme LLC | $389.81 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $358.43 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Astellas Pharma US INC | $313.89 | 2023-2025 | Padcev, Xtandi |
| Eisai INC. | $312.84 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $287.04 | 2022-2025 | Libtayo |
| Seagen INC. | $280.69 | 2023 | Padcev, Tukysa, Adcetris |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $267.43 | 2023-2025 | Orserdu |
| Glaxosmithkline, LLC. | $253.96 | 2023-2025 | Ojjaara, Jemperli, Shingrix |
| Genentech USA, INC. | $206.47 | 2023-2025 | Tecentriq, Alecensa, Rozlytrek |
| Genzyme Corporation | $174.36 | 2024-2025 | |
| Adc Therapeutics America, INC. | $174.24 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $136.16 | 2023-2025 | Xpovio |
| Incyte Corporation | $135.63 | 2023-2025 | Jakafi, Zynyz, Monjuvi |
| Jazz Pharmaceuticals INC. | $127.05 | 2023-2024 | |
| Lilly USA, LLC | $120.83 | 2023-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $120.64 | 2023-2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $118.64 | 2024-2025 | |
| Tempus Ai, INC | $114.41 | 2024-2025 | Xt Cdx |
| Tersera Therapeutics LLC | $112.66 | 2023-2025 | Zoladex, Xermelo |
| Dendreon Pharmaceuticals LLC | $86.36 | 2023 | Provenge |
| Deciphera Pharmaceuticals INC. | $78.91 | 2021-2025 | Qinlock, Romvimza |
| Foundation Medicine, INC. | $77.46 | 2023 | Foundationone Liquid Cdx, Foundationone Cdx |
| Kyowa Kirin, INC. | $66.52 | 2023-2025 | Poteligeo |
| Alexion Pharmaceuticals, INC. | $63.89 | 2023-2025 | Ultomiris |
| Sobi, INC | $61.24 | 2022-2024 | |
| Mirati Therapeutics, INC. | $61.01 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $56.39 | 2023-2025 | |
| Array Biopharma INC | $55.46 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Geron Corporation | $53.42 | 2025 | Rytelo |
| Aveo Pharmaceuticals, INC. | $46.33 | 2025 | |
| Adaptive Biotechnologies Corporation | $44.95 | 2025 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $43.43 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Agios Pharmaceuticals, INC. | $40.31 | 2023-2024 | Pyrukynd |
| Beigene USA, INC. | $39.71 | 2023-2024 | Brukinsa |
| Myriad Genetic Laboratories, INC. | $33.91 | 2023-2025 | Myrisk |
| Ipsen Biopharmaceuticals, INC | $33.77 | 2025 | Onivyde |
| Caris Mpi, INC. | $30.99 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $28.99 | 2023 | Imbruvica |
| Springworks Therapeutics, INC. | $27.85 | 2025 | Gomekli |
| Acrotech Biopharma INC. | $23.15 | 2025 | Beleodaq |
| Azurity Pharmaceuticals, INC. | $22.26 | 2025 | Danziten |
| Avyxa Pharma, LLC | $22.09 | 2025 | |
| Recordati_rare_diseases_inc. | $21.67 | 2025 | Enjaymo |
| Abbvie INC. | $20.17 | 2024 | |
| G1 Therapeutics, INC. | $19.46 | 2023 | Cosela |
| Teleflex LLC | $16.17 | 2023 | Arrow |
| Pharmaessentia USA Corporation | $15.93 | 2023 | Besremi |
| Pharmacosmos Therapeutics INC. | $15.90 | 2025 | Monoferric |
| Shield Therapeutics INC | $14.70 | 2024 | |
| Octapharma USA, INC. | $14.13 | 2023 | Octagam Immune Globulin (Human) |
| Coherus Oncology, INC. | $13.34 | 2023 | |
| Pharmaand Gmbh | $10.55 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.